Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

The move is the latest in the ongoing weight-loss drug price wars.

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

The steep monthly costs of GLP-1 medications have long been a major obstacle for many patients trying to find effective ...

WHO issues 1st guideline on GLP-1s recommending long-term use with behavioral therapy and notes pricing changes from major manufacturers.

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the ...

The market for GLP-1 drugs is projected to reach $180 billion in 2034, according to Morningstar Equity Research. Current ...

The first patient visit has taken place for the SURMOUNT-REAL UK clinical trial of Eli Lilly and Company’s weight-loss drug, tirzepatide.

Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing ...